29795041|t|Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).
29795041|a|Malignant melanoma is the most aggressive form of skin cancer and has a very low survival rate. Over 50% of melanomas harbor various BRAF mutations with the most common being the V600E. BRAFV600E mutation that causes constitutive activation of the MAPK pathway leading to drug-, immune-resistance, apoptosis evasion, proliferation, survival, and metastasis of melanomas. The ATP competitive BRAFV600E selective inhibitor, vemurafenib, has shown dramatic success in clinical trials; promoting tumor regression and an increase in overall survival of patients with metastatic melanoma. Regrettably, vemurafenib-resistance develops over an average of six months, which renders melanomas resistant to other therapeutic strategies. Elucidation of the underlying mechanism(s) of acquisition of vemurafenib-resistance and design of novel approaches to override resistance is the subject of intense clinical and basic research. In this review, we summarize recent developments in therapeutic approaches and clinical investigations on melanomas with BRAFV600E mutation to establish a new platform for the treatment of melanoma.
29795041	46	65	Metastatic Melanoma	Disease	MESH:D008545
29795041	88	99	Vemurafenib	Chemical	MESH:D000077484
29795041	101	110	BRAFV600E	ProteinMutation	tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:0;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:9606;CA#:123643
29795041	132	150	Malignant melanoma	Disease	MESH:D008545
29795041	182	193	skin cancer	Disease	MESH:D012878
29795041	240	249	melanomas	Disease	MESH:D008545
29795041	265	269	BRAF	Gene	673
29795041	311	316	V600E	ProteinMutation	tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:0;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:9606;CA#:123643
29795041	318	327	BRAFV600E	ProteinMutation	tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:0;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:9606;CA#:123643
29795041	478	488	metastasis	Disease	MESH:D009362
29795041	492	501	melanomas	Disease	MESH:D008545
29795041	507	510	ATP	Chemical	MESH:D000255
29795041	523	532	BRAFV600E	ProteinMutation	tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:0;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:9606;CA#:123643
29795041	554	565	vemurafenib	Chemical	MESH:D000077484
29795041	624	629	tumor	Disease	MESH:D009369
29795041	680	688	patients	Species	9606
29795041	694	713	metastatic melanoma	Disease	MESH:D008545
29795041	728	739	vemurafenib	Chemical	MESH:D000077484
29795041	805	814	melanomas	Disease	MESH:D008545
29795041	919	930	vemurafenib	Chemical	MESH:D000077484
29795041	1157	1166	melanomas	Disease	MESH:D008545
29795041	1172	1181	BRAFV600E	ProteinMutation	tmVar:p|SUB|V|600|E;HGVS:p.V600E;VariantGroup:0;CorrespondingGene:673;RS#:113488022;CorrespondingSpecies:9606;CA#:123643
29795041	1240	1248	melanoma	Disease	MESH:D008545
29795041	Association	MESH:D000255	RS#:113488022;HGVS:p.V600E;CorrespondingGene:673
29795041	Association	MESH:D009362	RS#:113488022;HGVS:p.V600E;CorrespondingGene:673
29795041	Negative_Correlation	MESH:D000077484	RS#:113488022;HGVS:p.V600E;CorrespondingGene:673
29795041	Association	MESH:D008545	RS#:113488022;HGVS:p.V600E;CorrespondingGene:673
29795041	Negative_Correlation	MESH:D000077484	MESH:D009369
29795041	Association	MESH:D000077484	MESH:D000255
29795041	Association	MESH:D008545	673
29795041	Negative_Correlation	MESH:D000077484	MESH:D008545
29795041	Association	MESH:D009362	673
29795041	Association	MESH:D008545	673

